dangers of glp 1 drugs Exploring the Side Effects GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning The promise and peril of

Tirzepatide is the agonist of GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor, which can reduce body weight and improve cardiac metabolism by subcutaneous injection once a week (Jastreboff et al 2022)

Am J Physiol Endocrinol Physiol 315: E1224E1231, 2018

However, now that these shortages have been resolved, compounded versions are no longer legally permitted to be made

They are authorized for treating obesity

In another phase II study, a fixed combination of a long-acting analogue of the islet peptide amylin (cagrilintide) with semaglutide at 2.4 mg (cagrisema) produced weight losses of 15.5% and 2.18% reductions in HbA 1c in obese individuals with T2DM [44]